Cite
HARVARD Citation
Ho, A. et al. (2022). Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). Journal of clinical oncology. 40 (17), pp. 1870-1878. [Online].